Based upon these findings, BRAF inhibitors (BRAFi) such as dabrafenib [42], the MEK inhibitors (MEKi) such as trametinib [43], and combinations thereof [44] that have recently been used for treating melanoma resulted in significantly improved overall survival in metastatic melanoma patients with BRAFV600E mutations. Here, MAP2K7 is linked to metastatic melanoma.